Regeneron
2Q Revenues: $1.6 billion (+9%)
2Q Earnings: $551 million (+42%)
YTD Revenues: $3.1 billion (+12%)
YTD Earnings: $1.0 billion (+62%)
Comments: U.S. sales of EYLEA (aflibercept) Injection were up 8% to $992 million in the quarter and global sales increased 13% to $1.7 billion. The company recently submitted a supplemental Biologics License Application (sBLA) for EYLEA for the treatment of diabetic retinopathy and submitted an sBLA for EYLEA in a pre-filled syringe. Bayer records net product sales of EYLEA outside the U.S. and Sanofi records global net product sales of Dupixent, Praluent, Kevzara, and ZALTRAP.